Member Directory - Pharmaceutical Advisory Board

Chair: Charles Flexner

Objectives:

  • Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
  • Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). He is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health.

Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie, where his areas of responsibility include viral diseases and cystic fibrosis. Dr. Cohen has extensive experience in clinical drug development for HIV and hepatitis C, and has been involved in the approval of Viekira Pak, Technivie, and Mavyret. 

Tine has a PhD in Veterinary Sciences from the University of Ghent, Belgium and earned her MBA in Pharmaceutical Management from Drexel LeBow College of Business. She has additional Masters degrees in Biology and Teaching. Tine is Compound Development Team Lead for Tuberculosis at Johnson & Johnson Global Public Health.

Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y. After completing her postdoctoral research fellowship in the department of Immunology at Smith Kline, she joined the antiviral research group as a Senior Research Biochemist at Merck in 1989.

Magali Hickey is the Director of Formulation Development at Alkermes Inc., a global biotechnology organization with a research and development facility located in Waltham, MA. Magali has over 10 years of experience in the pharmaceutical industry with interests focused on development of small molecules into viable drug products.

Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs. From 2004 to 2006, he was also Vice President of Drug Safety and Public Health. Dr. Rooney has been instrumental in the clinical development of the company's antiviral therapies, including treatments for HIV, hepatitis B and influenza.

Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina. Currently, he is Medicine Development Leader for the HIV integrase inhibitor cabotegravir, a long-acting injectable agent under investigation for both HIV prevention and treatment.